NASDAQ:ALBO

Albireo Pharma Stock Forecast, Price & News

$35.35
+1.08 (+3.15 %)
(As of 06/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$34.50
$35.73
50-Day Range
$28.90
$34.29
52-Week Range
$22.08
$49.00
Volume224,132 shs
Average Volume175,192 shs
Market Capitalization$678.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.56
30 days | 90 days | 365 days | Advanced Chart
Receive ALBO News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.


Albireo Pharma logo

About Albireo Pharma

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Social Links


MarketRank

Overall MarketRank

1.66 out of 5 stars

Medical Sector

375th out of 2,101 stocks

Pharmaceutical Preparations Industry

172nd out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions

Is Albireo Pharma a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Albireo Pharma stock.
View analyst ratings for Albireo Pharma
or view top-rated stocks.

What stocks does MarketBeat like better than Albireo Pharma?

Wall Street analysts have given Albireo Pharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Albireo Pharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Albireo Pharma?

Albireo Pharma saw a decline in short interest in May. As of May 28th, there was short interest totaling 1,790,000 shares, a decline of 15.6% from the May 13th total of 2,120,000 shares. Based on an average daily volume of 161,600 shares, the short-interest ratio is currently 11.1 days. Approximately 9.5% of the company's stock are short sold.
View Albireo Pharma's Short Interest
.

When is Albireo Pharma's next earnings date?

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Albireo Pharma
.

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings data on Wednesday, May, 5th. The biopharmaceutical company reported ($2.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($1.72) by $0.57. The biopharmaceutical company had revenue of $1.97 million for the quarter, compared to the consensus estimate of $2.65 million. Albireo Pharma had a negative net margin of 1,373.96% and a negative trailing twelve-month return on equity of 76.11%.
View Albireo Pharma's earnings history
.

How has Albireo Pharma's stock been impacted by Coronavirus?

Albireo Pharma's stock was trading at $17.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALBO stock has increased by 100.5% and is now trading at $35.35.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ALBO?

8 equities research analysts have issued 1 year price targets for Albireo Pharma's stock. Their forecasts range from $65.00 to $82.00. On average, they anticipate Albireo Pharma's share price to reach $72.00 in the next twelve months. This suggests a possible upside of 103.7% from the stock's current price.
View analysts' price targets for Albireo Pharma
or view top-rated stocks among Wall Street analysts.

Who are Albireo Pharma's key executives?

Albireo Pharma's management team includes the following people:
  • Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 58, Pay $1.13M)
  • Ms. Martha J. Carter, Chief Regulatory Officer (Age 69, Pay $745.73k)
  • Dr. Patrick T. Horn, Chief Medical Officer (Age 66, Pay $814.95k)
  • Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
  • Dr. Jan P. Mattsson, Chief Scientific Officer, MD (Sweden) & Co-Founder (Age 57)
  • Mr. Simon Nicolas Reade Harford, CFO & Treasurer (Age 60)
  • Ms. Joan Connolly, Chief Technology Officer
  • Mr. Jason G. Duncan, Chief Legal Officer, Gen. Counsel & Sec. (Age 47)
  • Ms. Michelle Graham, Chief HR Officer (Age 54)
  • Dr. Kristina TorfgÃ¥rd, VP & Global Project Head

Who are some of Albireo Pharma's key competitors?

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (12.30%), BlackRock Inc. (6.66%), Chicago Capital LLC (3.59%), Dimensional Fund Advisors LP (1.84%), Geode Capital Management LLC (1.49%) and Goldman Sachs Group Inc. (1.17%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc and Simon NR Harford.
View institutional ownership trends for Albireo Pharma
.

Which institutional investors are selling Albireo Pharma stock?

ALBO stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Federated Hermes Inc., Millennium Management LLC, Bank of Montreal Can, Northern Trust Corp, Ameriprise Financial Inc., Morgan Stanley, and Los Angeles Capital Management LLC. Company insiders that have sold Albireo Pharma company stock in the last year include Jan Mattsson, Jason Duncan, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, and Simon NR Harford.
View insider buying and selling activity for Albireo Pharma
or view top insider-selling stocks.

Which institutional investors are buying Albireo Pharma stock?

ALBO stock was bought by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Dimensional Fund Advisors LP, Platinum Investment Management Ltd., Endurant Capital Management LP, Citigroup Inc., Rafferty Asset Management LLC, BlackRock Inc., and Geode Capital Management LLC. Company insiders that have bought Albireo Pharma stock in the last two years include Life Sciences Maste Perceptive, and Perceptive Advisors Llc.
View insider buying and selling activity for Albireo Pharma
or or view top insider-buying stocks.

How do I buy shares of Albireo Pharma?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $35.35.

How much money does Albireo Pharma make?

Albireo Pharma has a market capitalization of $678.54 million and generates $8.31 million in revenue each year. The biopharmaceutical company earns $-107,630,000.00 in net income (profit) each year or ($6.73) on an earnings per share basis.

How many employees does Albireo Pharma have?

Albireo Pharma employs 90 workers across the globe.

When was Albireo Pharma founded?

Albireo Pharma was founded in 2003.

What is Albireo Pharma's official website?

The official website for Albireo Pharma is www.albireopharma.com.

Where are Albireo Pharma's headquarters?

Albireo Pharma is headquartered at 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at (857) 254-5555 or via email at [email protected]


This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.